Heron Therapeutics (HRTX) PT Set at $40.00 by Cantor Fitzgerald

Heron Therapeutics (NASDAQ:HRTX) has been assigned a $40.00 target price by Cantor Fitzgerald in a report released on Sunday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 30.93% from the company’s previous close.

HRTX has been the topic of a number of other reports. Mizuho reiterated a “buy” rating and issued a $28.00 target price on shares of Heron Therapeutics in a report on Tuesday, January 16th. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Leerink Swann initiated coverage on Heron Therapeutics in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 price target for the company. Cowen reissued a “buy” rating on shares of Heron Therapeutics in a research report on Monday, March 19th. Finally, Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research report on Friday, March 2nd. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Heron Therapeutics has an average rating of “Buy” and an average target price of $35.92.

How to Become a New Pot Stock Millionaire

Shares of HRTX opened at $30.55 on Friday. Heron Therapeutics has a 12-month low of $12.70 and a 12-month high of $32.70. The firm has a market capitalization of $2,213.04, a P/E ratio of 8.37 and a beta of 1.86.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.29). Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. The firm had revenue of $10.05 million during the quarter, compared to the consensus estimate of $9.00 million. analysts predict that Heron Therapeutics will post -2.48 earnings per share for the current year.

In other news, CEO Barry D. Quart sold 100,000 shares of the firm’s stock in a transaction on Monday, March 19th. The stock was sold at an average price of $29.75, for a total transaction of $2,975,000.00. Following the completion of the sale, the chief executive officer now directly owns 167,993 shares of the company’s stock, valued at approximately $4,997,791.75. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Kimberly Manhard sold 18,000 shares of the firm’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $30.00, for a total value of $540,000.00. Following the sale, the vice president now directly owns 18,000 shares of the company’s stock, valued at $540,000. The disclosure for this sale can be found here. Insiders sold a total of 218,000 shares of company stock valued at $5,990,000 over the last three months. 19.93% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in HRTX. Wells Fargo & Company MN increased its position in shares of Heron Therapeutics by 202.1% during the 3rd quarter. Wells Fargo & Company MN now owns 130,374 shares of the biotechnology company’s stock valued at $2,106,000 after purchasing an additional 87,212 shares during the last quarter. Private Asset Management Inc. increased its position in shares of Heron Therapeutics by 190.6% during the 4th quarter. Private Asset Management Inc. now owns 86,975 shares of the biotechnology company’s stock valued at $1,574,000 after purchasing an additional 57,050 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Heron Therapeutics by 50.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 242,934 shares of the biotechnology company’s stock valued at $4,398,000 after purchasing an additional 81,735 shares during the last quarter. Fox Run Management L.L.C. increased its position in shares of Heron Therapeutics by 27.5% during the 4th quarter. Fox Run Management L.L.C. now owns 22,050 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 4,750 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in shares of Heron Therapeutics by 20.6% during the 4th quarter. Fisher Asset Management LLC now owns 121,069 shares of the biotechnology company’s stock valued at $2,191,000 after purchasing an additional 20,705 shares during the last quarter. 97.38% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics (HRTX) PT Set at $40.00 by Cantor Fitzgerald” was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://weekherald.com/2018/04/24/heron-therapeutics-hrtx-pt-set-at-40-00-by-cantor-fitzgerald.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply